Advertisement

Topics

Zynerba shares plunge as cannabis-based epilepsy gel fails study

11:42 EDT 7 Aug 2017 | Reuters

(Reuters) - Zynerba Pharmaceuticals Inc's stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.

Original Article: Zynerba shares plunge as cannabis-based epilepsy gel fails study

NEXT ARTICLE

More From BioPortfolio on "Zynerba shares plunge as cannabis-based epilepsy gel fails study"

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...